Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Foster Dykema Cabot & Partners LLC

Foster Dykema Cabot & Partners LLC trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,923 shares of the pharmaceutical company’s stock after selling 532 shares during the period. Vertex Pharmaceuticals accounts for about 1.9% of Foster Dykema Cabot & Partners LLC’s holdings, making the stock its 19th largest holding. Foster Dykema Cabot & Partners LLC’s holdings in Vertex Pharmaceuticals were worth $27,121,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in VRTX. Brighton Jones LLC increased its stake in Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. Avantax Advisory Services Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 10.5% in the 1st quarter. Avantax Advisory Services Inc. now owns 12,674 shares of the pharmaceutical company’s stock valued at $6,145,000 after buying an additional 1,203 shares in the last quarter. Cetera Investment Advisers grew its position in shares of Vertex Pharmaceuticals by 20.0% in the 1st quarter. Cetera Investment Advisers now owns 64,774 shares of the pharmaceutical company’s stock valued at $31,404,000 after buying an additional 10,817 shares during the last quarter. HB Wealth Management LLC raised its stake in Vertex Pharmaceuticals by 21.5% during the 1st quarter. HB Wealth Management LLC now owns 10,656 shares of the pharmaceutical company’s stock worth $5,166,000 after acquiring an additional 1,889 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Vertex Pharmaceuticals by 10.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 384,710 shares of the pharmaceutical company’s stock valued at $186,515,000 after acquiring an additional 35,233 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.1%

NASDAQ:VRTX opened at $426.76 on Monday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68. The stock’s 50 day simple moving average is $411.39 and its 200-day simple moving average is $425.00. The firm has a market cap of $108.28 billion, a P/E ratio of 30.50 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, topping the consensus estimate of $4.58 by $0.22. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the company earned $4.38 earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on VRTX shares. UBS Group decreased their price objective on shares of Vertex Pharmaceuticals from $553.00 to $546.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Evercore ISI decreased their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research report on Thursday, September 11th. HC Wainwright dropped their price target on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research note on Tuesday, August 5th. Canaccord Genuity Group reduced their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research note on Wednesday, August 6th. Finally, Leerink Partners raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price objective for the company from $458.00 to $456.00 in a report on Thursday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $491.95.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 53,604 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $440.72, for a total value of $23,624,354.88. Following the sale, the chairman owned 24,026 shares of the company’s stock, valued at $10,588,738.72. The trade was a 69.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.